CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5,432.69%
Return on EquityN/A
Return on Assets-110.07%
Miscellaneous
EmployeesN/A
Outstanding Shares19,520,000
Market Cap$25.49
CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) released its earnings results on Tuesday, May, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter. The company earned $0.13 million during the quarter. View CEL-SCI's Earnings History.
When is CEL-SCI's next earnings date?
What is the consensus analysts' recommendation for CEL-SCI?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Are investors shorting CEL-SCI?
CEL-SCI saw a drop in short interest in June. As of June 29th, there was short interest totalling 667,125 shares, a drop of 39.8% from the June 15th total of 1,108,178 shares. Based on an average daily volume of 1,103,376 shares, the short-interest ratio is presently 0.6 days. Approximately 3.0% of the shares of the company are sold short. View CEL-SCI's Current Options Chain.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Tissue Regenix Group (TRX), Covalon Technologies (COV), Matinas BioPharma (MTNB), Motif Bio (MTFB), Innovation Pharmaceuticals (IPIX), 4d Pharma (DDDD), Helix Biopharma (HBP), Ergomed (ERGO), Cardiome Pharma (COM), GB Sciences (GBLX), OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT) and IntelGenx Technologies (IGX).
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the folowing people:
- Mr. Geert R. Kersten, Chief Exec., Financial & Accounting Officer, Treasurer and Director (Age 59)
- Ms. Patricia B. Prichep, Sr. VP of Operations (Age 67)
- Dr. Eyal Talor, Chief Scientific Officer (Age 62)
- Dr. Daniel H. Zimmerman, Sr. VP of Research - Cellular Immunology (Age 77)
- Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 76)
Has CEL-SCI been receiving favorable news coverage?
News coverage about CVM stock has trended somewhat positive this week, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CEL-SCI earned a media sentiment score of 0.08 on Accern's scale. They also gave news articles about the company an impact score of 45.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of CEL-SCI?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CEL-SCI's stock price today?
One share of CVM stock can currently be purchased for approximately $0.93.
How big of a company is CEL-SCI?
CEL-SCI has a market capitalization of $25.49 million.
How can I contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
